Sugi Predict

Sugi Predict / Compounds / SCHEMBL5945366

SCHEMBL5945366

SCHEMBL5945366

N[C@@H](c1ccccc1)C1CC1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 4/20 0.54
▸ DPP4 P27487 2/20 0.48
▸ F2 P00734 1/20 0.48
▸ AKT2 P31751 1/20 0.44
▸ OPRM1 P35372 4/20 0.42
▸ OPRD1 P41143 4/20 0.42
▸ OPRK1 P41145 4/20 0.42
▸ OPRL1 P41146 4/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1423740 1.00 IDO1 (0.54) IDO1DPP4F2AKT2OPRM1
SCHEMBL2149539 1.00 IDO1 (0.54) IDO1DPP4F2AKT2OPRM1
Hydrochloric Acid SCHEMBL2309180 0.98 IDO1 (0.55) IDO1DPP4F2AKT2OPRM1
Hydrochloric Acid SCHEMBL3323789 0.98 IDO1 (0.55) IDO1DPP4F2AKT2OPRM1
Hydrochloric Acid SCHEMBL18336573 0.98 IDO1 (0.55) IDO1DPP4F2AKT2OPRM1
Hydrochloric Acid SCHEMBL2309178 0.95 IDO1 (0.50) IDO1DPP4F2AKT2OPRM1
SCHEMBL8572567 0.91 IDO1 (0.47) IDO1DPP4F2AKT2OPRM1
SCHEMBL11885874 0.91 IDO1 (0.50) IDO1DPP4F2AKT2OPRM1
SCHEMBL2677106 0.91 IDO1 (0.50) IDO1DPP4F2AKT2OPRM1
SCHEMBL2677194 0.91 IDO1 (0.55) IDO1DPP4F2AKT2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12338262-B2 Modulators of TNF-alpha activity FORWARD THERAPEUTICS, INC. (US) 2025-06-24 — — US disclosed
US-20240279258-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. 2024-08-22 — — US disclosed
US-11987597-B2 Modulators of TNF-α activity FORWARD THERAPEUTICS, INC. (US) 2024-05-21 — — US disclosed
US-20240076306-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. 2024-03-07 — — US disclosed
WO-2023240253-A2 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
WO-2023240253-A2 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
US-11371067-B2 Transaminase reactions CODEXIS, INC. (US) 2022-06-28 — — US disclosed
US-20200362377-A1 TRANSAMINASE REACTIONS INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2020-11-19 — — US disclosed
US-20200332321-A1 ENGINEERED TRANSAMINASE POLYPEPTIDES AND USES THEREOF Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) 2020-10-22 — — US disclosed
US-10767202-B2 Transaminase reactions CODEXIS, INC. (US) 2020-09-08 — — US disclosed
US-20070021494-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION AND PHARMACOPEIA, INC. 2007-01-25 — — US disclosed
US-20070021494-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION AND PHARMACOPEIA, INC. 2007-01-25 — — US disclosed
US-20060161004-A1 Novel compounds GLAXOSMITHKLINE SPA 2006-07-20 — — US disclosed
US-20050070574-A1 Novel compounds GLAXOSMITHKLINE SPA AND LABORATOIRE 2005-03-31 — — US disclosed
US-20040102633-A1 Novel compounds GLAXOSMITHKLINE S.P.A. (IT) 2004-05-27 — — US disclosed
EP-1339691-A1 NOVEL COMPOUNDS GlaxoSmithKline S.p.A. (IT) 2003-09-03 — — EP disclosed
WO-2002044154-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE SPA (IT) 2002-06-06 — — WO disclosed
EP-0779296-A2 D-alpha-aminoalkanoyl-(S)-N-alpha-alkylbenzyl amides useful as intermediates for artificial sweeteners THE COCA-COLA COMPANY (US) 1997-06-18 — — EP disclosed
WO-1995017418-A2 NOVEL INTERMEDIATES FOR THE SYNTHESIS OF L-ASPARTYL-D-α-AMINOALKANOYL-(S)-N-α-ALKYLBENZYL AMIDES USEFUL AS ARTIFICIAL SWEETENERS THE COCA-COLA COMPANY (US) 1995-06-29 — — WO disclosed
US-5286509-A L-aspartyl-D-α-aminoalkanoyl-(S)-N-alpha-alkylbenzyl amides useful as artificial sweeteners THE COCA-COLA COMPANY (US) 1994-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070574-A1 Novel compounds NR1H3, NR1H2, CNR1 IDO1 4335/4885DPP4 3366/4885F2 3797/4885
US-20070021494-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands CCR1, ACKR3, CXCR1 IDO1 991/4885DPP4 2687/4885F2 1379/4885
US-20060161004-A1 Novel compounds SLC10A1, ABCB11, AQP1 IDO1 4583/4885DPP4 905/4885F2 396/4885
US-20240279258-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, TNFRSF1A, NFKBIA IDO1 1754/4885DPP4 2004/4885F2 3011/4885
US-11987597-B2 Modulators of TNF-α activity TNF, TNFRSF1A, NFKBIA IDO1 1679/4885DPP4 1760/4885F2 3128/4885
US-20240076306-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, TNFRSF1A, NFKBIA IDO1 1754/4885DPP4 2004/4885F2 3011/4885
US-20040102633-A1 Novel compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, NR1H3 IDO1 3767/4885DPP4 2248/4885F2 3190/4885
US-12338262-B2 Modulators of TNF-alpha activity TNF, TNFRSF1A, NFKBIA IDO1 1754/4885DPP4 2004/4885F2 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.